Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.42 |
| ▸ | NNMT | P40261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 3/20 | 0.39 |
| ▸ | GABRD | O14764 | 3/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.39 |
| ▸ | GABRE | P78334 | 3/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.39 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.39 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.39 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Aminopyridine SCHEMBL667672 | 0.88 | NOS3 (0.53) | MKNK1MKNK2NNMTSMN1; SMN2GABRP | |
| SCHEMBL5119246 | 0.83 | KMO (0.49) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL16421042 | 0.81 | SORD (0.44) | MKNK1MKNK2GABRPGABRDGABRA1 | |
| Potassium Ion SCHEMBL30341567 | 0.79 | GABRP (0.37) | MKNK1MKNK2NNMTSMN1; SMN2GABRP | |
| SCHEMBL30380815 | 0.79 | GABRP (0.37) | MKNK1MKNK2NNMTSMN1; SMN2GABRP | |
| SCHEMBL163294 | 0.78 | KDM4E (0.37) | MKNK1MKNK2NNMTSMN1; SMN2ROCK1 | |
| SCHEMBL163293 | 0.78 | MKNK1 (0.38) | MKNK1MKNK2NNMTSMN1; SMN2GABRP | |
| SCHEMBL30521607 | 0.78 | ADORA3 (0.42) | MKNK1MKNK2NNMTROCK1KDM4B | |
| SCHEMBL3906535 | 0.78 | ADORA3 (0.42) | MKNK1MKNK2NNMTROCK1KDM4B | |
| SCHEMBL15102676 | 0.78 | PRSS1 (0.37) | MKNK1MKNK2PLAUHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370815-A1 | ANTI-INFLAMMATORY COMPOSITIONS AND METHODS | Searete LLC (US) | 2011-10-05 | — | — | EP | claimed |
| WO-2010065118-A1 | ANTI-INFLAMMATORY COMPOSITIONS AND METHODS | SEARETE, LLC (US) | 2010-06-10 | — | — | WO | claimed |
| EP-3983081-B1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4698519-A1 | 3,5-DIAMINOTRIAZOLE DERIVATIVES AND USES THEREOF FOR TREATING OCULAR DISEASES | Centre National de la Recherche Scientifique (FR) | 2026-02-25 | — | — | EP | disclosed |
| US-20260007668-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12377097-B2 | Aminopyrimidine amide autophagy inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2025-08-05 | — | — | US | disclosed |
| JP-2025004153-A | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | デシフェラ・ファーマシューティカルズ，エルエルシー | 2025-01-14 | — | — | JP | disclosed |
| CN-119241444-A | Aminopyrimidinamide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-119241444-A | Aminopyrimidinamide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-119176782-A | Aminopyrimidinamide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2024-12-24 | — | — | CN | disclosed |
| CN-119176782-A | Aminopyrimidinamide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2024-12-24 | — | — | CN | disclosed |
| US-20100137844-A1 | Delivery devices for modulating inflammation | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-06-03 | — | — | US | disclosed |
| US-20100137787-A1 | Delivery devices for modulating inflammation | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-06-03 | — | — | US | disclosed |
| US-20100137247-A1 | Anti-inflammatory compositions and methods | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-06-03 | — | — | US | disclosed |
| US-20100135908-A1 | Delivery devices for modulating inflammation | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-06-03 | — | — | US | disclosed |
| US-20100136095-A1 | Systems for modulating inflammation | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-06-03 | — | — | US | disclosed |
| US-20100136096-A1 | Systems for modulating inflammation | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-06-03 | — | — | US | disclosed |
| US-20100137843-A1 | Delivery devices for modulating inflammation | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-06-03 | — | — | US | disclosed |
| US-20100137246-A1 | Anti-inflammatory compositions and methods | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-06-03 | — | — | US | disclosed |
| US-20100136097-A1 | Systems for modulating inflammation | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12377097-B2 | Aminopyrimidine amide autophagy inhibitors and methods of use thereof | BECN1, SQSTM1, ATG7 | MKNK1 493/4885MKNK2 591/4885NNMT 50/4885 |
| US-20260007668-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | MKNK1 1509/4885MKNK2 2322/4885NNMT 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.